Nathalie Ganne-Carrié, Pierre Nahon  Journal of Hepatology 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Inflammasomes in liver diseases
Tiny RNA with great effects: miR-155 in alcoholic liver disease
The GAPs between hepatocellular carcinoma and RAS
PNPLA3 gene in liver diseases
Figure 3 Neutrophils in liver inflammation
Pathological roles of purinergic signaling in the liver
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
Pathways of liver injury in alcoholic liver disease
The inflammasome in liver disease
Reactive oxygen species in the normal and acutely injured liver
Obesity, inflammation, and liver cancer
T. Vescovo, G. Refolo, G. Vitagliano, G.M. Fimia, M. Piacentini 
Inflammation and Colon Cancer
Gianluca Tell, Carlo Vascotto, Claudio Tiribelli  Journal of Hepatology 
Biochemical and physiological effects from exhaust emissions
Lymphotoxins: New Targets for Hepatocellular Carcinoma
New Animal Models for Parkinson's Disease
Alcohol and toxicity Journal of Hepatology
Volume 49, Issue 5, Pages (November 2008)
Data Triumph at C Cancer Cell
The gut microbiota and the liver
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute- on-chronic liver failure  Manuel Romero-Gómez, Sara Montagnese, Rajiv.
Living donor liver transplantation: is the hype over?
Pathological bacterial translocation in liver cirrhosis
Biochemical and physiological effects from exhaust emissions
Mesenchymal stromal cell therapy for liver diseases
Inflammation and portal hypertension – The undiscovered country
Immunopathogenesis of Rheumatoid Arthritis
European Association for the Study of the Liver  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
I. Carmona, P. Cordero, J. Ampuero, A. Rojas, M. Romero-Gómez 
Benjamin L. Woolbright, Hartmut Jaeschke  Journal of Hepatology 
Targeting gut flora to prevent progression of hepatocellular carcinoma
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Targets for immunotherapy of liver cancer
Mechanisms of iron hepatotoxicity
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts  Chiara Raggi, Pietro Invernizzi,
Daniel J. Felmlee, Thomas F. Baumert  Journal of Hepatology 
Genomic risk of hepatitis C-related hepatocellular carcinoma
Autophagy in the liver Journal of Hepatology
Pathways of liver injury in alcoholic liver disease
Pierre Nahon, Jessica Zucman-Rossi  Journal of Hepatology 
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Microbes, Microbiota, and Colon Cancer
Marcel Klingenberg, Akiko Matsuda, Sven Diederichs, Tushar Patel 
Volume 63, Issue 2, Pages (August 2015)
Senescence in chronic liver disease: Is the future in aging?
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Inflammation-Associated Cancer Development in Digestive Organs: Mechanisms and Roles for Genetic and Epigenetic Modulation  Tsutomu Chiba, Hiroyuki Marusawa,
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
NASH animal models: Are we there yet?
Figure 1 Chronic inflammation and DNA damage in people with SLE
Volume 61, Issue 1, Pages S79-S90 (November 2014)
Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva 
Therapeutic strategies in inflammasome mediated diseases of the liver
Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma
Inflammation, ROS, and Mutagenesis
Silvia Affò, Ramón Bataller  Journal of Hepatology 
Volume 65, Issue 4, Pages (October 2016)
Pathogenesis of cholestatic hepatitis C
Inflammatory pathways in alcoholic steatohepatitis
Volume 58, Issue 4, Pages (April 2013)
Genetics of hepatocellular carcinoma: The next generation
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Tenets of PTEN Tumor Suppression
Presentation transcript:

Hepatocellular carcinoma in the setting of alcohol-related liver disease  Nathalie Ganne-Carrié, Pierre Nahon  Journal of Hepatology  Volume 70, Issue 2, Pages 284-293 (February 2019) DOI: 10.1016/j.jhep.2018.10.008 Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Geographical distribution of the contribution of alcohol to absolute primary liver cancer deaths in Europe for both genders (adapted from Akinyemiju T et al. JAMA Oncol 2017;3:1683–1691, Table S10e). Journal of Hepatology 2019 70, 284-293DOI: (10.1016/j.jhep.2018.10.008) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Biological pathways involved in alcohol-mediated liver carcinogenesis. Ethanol is first metabolised by alcohol dehydrogenase (ADH) into carcinogenic acetaldehyde, which causes major cell damage by forming DNA and protein adducts. CYP2E1 also triggers the formation of acetaldehyde and reactive oxygen species (ROS). Oxidative stress secondary to ROS accumulation damages cell components through lipid peroxidation and DNA mutagenesis via the formation of adducts and the impairment of repair mechanisms. The effects of iron and lipid accumulation usually observed in ALD also participate in ROS accumulation, and further aggravate the deleterious effects of oxidative stress. In addition, alcohol promotes inflammation via the translocation of gut bacteria and lipopolysaccharide, which trigger the production of pro-inflammatory cytokines and chemokines implicated in both the anti-tumour immune response and ROS formation. Acetaldehyde also alters methyl transfer, leading to DNA hypomethylation associated with modifications to gene expression (oncogenes and tumour suppressor genes). The principal variants reported as being potential genetic modifiers of the liver cancer risk in patients with ALD are depicted as a function of their specific interactions with these molecular pathways. Journal of Hepatology 2019 70, 284-293DOI: (10.1016/j.jhep.2018.10.008) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions